What is Veracyte Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Veracyte's interest expense for the
three
months ended in Dec. 2024 was $ 0.0 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.0 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Veracyte's Operating Income for the
three
months ended in Dec. 2024 was $ 6.0 Mil. Veracyte's Interest Expense for the
three
months ended in Dec. 2024 was $ 0.0 Mil.
GuruFocus does not calculate Veracyte's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Veracyte Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veracyte (NAS:VCYT) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Veracyte's Interest Expense for the
three
months ended in Dec. 2024 was $0.0 Mil. Its
Operating Income
for the
three
months ended in Dec. 2024 was $6.0 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2024 was $43.2 Mil.
Veracyte's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as
| GuruFocus does not calculate Veracyte's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Veracyte Inc has enough cash to cover all of its debt. Its financial situation is stable.
Veracyte Business Description
Traded in Other Exchanges
Address
6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Executives
| John Leite |
officer: Chief Commercial Officer-CLIA |
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
| Phillip G. Febbo |
officer: Chief Scientific & Med Officer |
C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
| Marc Stapley |
officer: Chief Executive Officer |
9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121 |
| Annie Mcguire |
officer: SVP, General Counsel |
C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
| Rebecca Chambers |
officer: Chief Financial Officer |
3052 ORCHARD DR., SAN JOSE CA 95134 |
| Karin Eastham |
director |
C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037 |
| Jonathan Wygant |
officer: VP, Chief Accounting Officer |
3750 TORREY VIEW COURT, SAN DIEGO X1 92130 |
| Robert S Epstein |
director |
|
| Evan/ Fa Jones |
director |
C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878 |
| Jens Holstein |
director |
C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
| Muna Bhanji |
director |
C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
| John L Bishop |
director |
|
| Bonnie H Anderson |
director, officer: President & CEO |
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
| Giulia C Kennedy |
officer: Chief Scientific & Med Officer |
338 MAIN STREET #26E, SAN FRANCISCO CA 94105 |
| Eliav Barr |
director |
C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VCYT has been successfully added to your 